The 2021 ESMO Congress featured a lot of new advancements in non-small cell lung cancer (NSCLC) treatment. Here to provide a recap of one of those treatments for NSCLC patients with HER2 mutations is Dr. Alexander Spira, Co-Director of the VCS Research Institute, Director of the Thoracic and Phase I Program, and Clinical Assistant Professor at Johns Hopkins.